Abstract:Objective To compare the therapeutic effect of TACE combined with or without endovascular implantation of iodine-125 seeds strand for hepatocellular carcinoma ( HCC) with extensive portal vein tumor thrombus(PVTT)with randomized design.Methods From May-2011 to Dec 2012,62 patients of HCC with extensive PVTT who received TACE were randomized divided into group A ( conbined with , 30 cases)and group B(without,32 cases)endovascular implantation of iodine-125 seeds strand were analyzed retrospectively .TACE was performed after the iodine-125 seed strand implanted in the target segment of PVTT.Adverse events , laboratory tests and abdominal constrast CT results between two groups were compared.Kaplan-Meier method was used for analyzing for survival rate .Results The objective remission rate of lesions was 10.0%(CR in 1 and PR in 6)in group A and 28.1%(CR in 2,PR in 7)in group B(χ2 =3.259,P=0.071).The mean number of iodine-125 seed was 20.4 ±4.4(14-32) for every patient.The recanalization rate of portal vein was 28.1%in group B higher than 0 in group A(χ2 =7.734,P=0.005). Technical success rate was 100.0% for implantation of iodine-125 seeds strand in the target segment of PVTT.No serious procedure related complications occurred in two group .The mean and median survival time was(153.8 ±9.9) d(95%CI:134.5-173.1) and(150.0 ±10.9) d(95%CI:128.6-171.4) in Group A and(221.5 ±19.2)d 95%CI:183.8-259.1)and(190.0 ±24.7)d 95%CI:141.6-238.4)in Group B, respectively(χ2 =10.973,P=0.001)(HR(A︰B) =2.577,95%CI:1.437-4.623,P=0.001).The 90, 180,360 d cumulative survival rates were 89.7%,28.7%and 0 in group A and 96.8%,56.0%and 15.2%in group B,respectively.In group with recanalization of portal vein (group B1,9 cases),the mean and median survival time were(306.9 ±45.6)d(95%CI:217.5-396.2)and(264.0 ±41.7)d(95%CI:182.3-345.7), respectively and the 90,180,360 d cumulative survival rates were 100.0%,87.5%and 40.0%,respectively. While in group without recanalization of portal vein (group B2,23 cases),the mean and median survival time were(189.5 ±16.5) d (95%CI:157.2-221.9) and (175.0 ±20.4) d (95%CI:134.9-215.1), respectively and the 90,180,360 d cumulative survival rates were 95.5%,43.2%and 6.4%,respectively. There was statistically significant difference between two groups (χ2 =5.105,P=0.024)(HR(B2︰B1) =2.960,95%CI:1.100-7.969,P=0.032).Conclusion TACE combined with endovascular implantation of iodine-125 seeds strand is an effective treatment for HCC with extensive PVTT .

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Evaluation of the Curative Effect of Transcatheter Arterial Chemoembolization Via Hepatic Artery Combined with Percutaneous Ethanol Injection for the Treatment of Primary Hepatocellular Carcinoma

[Clinical Effect of Terminal Branches Portal Vein Embolization Combined with Transcatheter Arterial Chemoembolization on Liver Neoplasms].

Portal Vein Stenting Combined 125I Particle Implanted Followed by Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Transcatheter arterial chemoembolization combined with endovascular 125I seed strip implantation for primary hepatocellular carcinoma associated with portal vein tumor thrombus：analysis of curative effect

Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand

TACE Combined with Portal Vein Tumor Thrombus 125I Seed Implantation in the Treatment of HCC with Hepatic Arterioportal Shunts

Treatment of Hepatocellular Carcinoma with Tumor Thrombus with the Use of Iodine-125 Seed Strand Implantation and Transarterial Chemoembolization: A Propensity-Score Analysis

Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis.

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

[Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein].

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Efficacy and safety of transcatheter arterial chemoembolization combined with either 125I seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective comparative study

HCC with Main Portal Vein Tumor Thrombus Treated by Stent Placement and TACE Combined with Endovascular Brachytherapy or Three Dimensional Conformal Radiotherapy

Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without

Evaluation of the Therapeutic Effect of Hepatic Arterial Chemoembolization Combined with Portal Chemoembolization for Advanced Hepatic Carcinomas

Transartenal chemoembolization and portal vein chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus